Multivariate analysis of cardiotoxicity related to HER2-targeted therapy in early breast cancer showed that age, coronary heart disease, left chest wall radiotherapy, and anthracene sequential therapy were independent risk factors for cardiotoxicity (P < 0.05), (Fig. 2). Here, ERBB2 is linked to breast cancer.